Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China

Hengcong Liu, Juanjuan Zhang, Jun Cai, Xiaowei Deng, Cheng Peng, Xinghui Chen, Juan Yang, Qianhui Wu, Xinhua Chen, Zhiyuan Chen, Wen Zheng, Cécile Viboud, Wenhong Zhang, Marco Ajelli, Hongjie Yu
doi: https://doi.org/10.1101/2021.07.23.21261013
Hengcong Liu
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juanjuan Zhang
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
2Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Cai
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Deng
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Peng
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinghui Chen
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Yang
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
2Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China
3Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianhui Wu
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinhua Chen
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiyuan Chen
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen Zheng
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Viboud
4Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenhong Zhang
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Ajelli
5Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA
6Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongjie Yu
1Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
2Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China
3Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yhj@fudan.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background To allow a return to a pre-COVID-19 lifestyle, virtually every country has initiated a vaccination program to mitigate severe disease burden and control transmission. However, it remains to be seen whether herd immunity will be within reach of these programs.

Methods We developed a data-driven model of SARS-CoV-2 transmission for China, a population with low prior immunity from natural infection. The model is calibrated considering COVID-19 natural history and the estimated transmissibility of the Delta variant. Three vaccination programs are tested, including the one currently enacted in China and model-based estimates of the herd immunity level are provided.

Results We found that it is unlike to reach herd immunity for the Delta variant given the relatively low efficacy of the vaccines used in China throughout 2021, the exclusion of underage individuals from the targeted population, and the lack of prior natural immunity. We estimate that, assuming a vaccine efficacy of 90% against the infection, vaccine-induced herd immunity would require a coverage of 93% or higher of the Chinese population. However, even when vaccine-induced herd immunity is not reached, we estimated that vaccination programs can reduce SARS-CoV-2 infections by 53-58% in case of an epidemic starts to unfold in the fall of 2021.

Conclusions Efforts should be taken to increase population’s confidence and willingness to be vaccinated and to guarantee highly efficacious vaccines for a wider age range.

Competing Interest Statement

H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.

Funding Statement

The study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), European Union Grant 874850 MOOD (MOOD 000), and the National Institute for Health Research (NIHR) (grant no. 16/137/109) using UK aid from the UK Government to support global health research. We also acknowledge grant from Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response (20dz2260100). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committee approval was not needed in this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • replace the results of wild strain with Delta variant

Data Availability

The availability of all data can be addressed to the correspondence author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China
Hengcong Liu, Juanjuan Zhang, Jun Cai, Xiaowei Deng, Cheng Peng, Xinghui Chen, Juan Yang, Qianhui Wu, Xinhua Chen, Zhiyuan Chen, Wen Zheng, Cécile Viboud, Wenhong Zhang, Marco Ajelli, Hongjie Yu
medRxiv 2021.07.23.21261013; doi: https://doi.org/10.1101/2021.07.23.21261013
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China
Hengcong Liu, Juanjuan Zhang, Jun Cai, Xiaowei Deng, Cheng Peng, Xinghui Chen, Juan Yang, Qianhui Wu, Xinhua Chen, Zhiyuan Chen, Wen Zheng, Cécile Viboud, Wenhong Zhang, Marco Ajelli, Hongjie Yu
medRxiv 2021.07.23.21261013; doi: https://doi.org/10.1101/2021.07.23.21261013

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1256)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10047)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2481)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1652)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11888)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2301)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1257)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2294)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)